Spartalizumab (INN;[1] development code PDR001) is a monoclonal antibody and checkpoint inhibitor that is being investigated for melanoma.

Spartalizumab
Monoclonal antibody
TypeWhole antibody
SourceHumanized
TargetPD-1 (CD279)
Clinical data
Other namesPDR001
ATC code
  • none
Identifiers
CAS Number
UNII
KEGG

This drug is being developed by Novartis. As of 2018, spartalizumab is undergoing Phase III trials.[2]

References

edit
  1. ^ World Health Organization (2017). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 117" (PDF). WHO Drug Information. 31 (2).
  2. ^ Kaplon H, Muralidharan M, Schneider Z, Reichert JM (2020). "Antibodies to watch in 2020". mAbs. 12 (1): 1703531. doi:10.1080/19420862.2019.1703531. PMC 6973335. PMID 31847708.